DCAF12

(redirected from CT102)

DCAF12

A gene on chromosome 1q24.2 that encodes a protein which may act as a substrate receptor for the CUL4-DDB1 E3 ubiquitin-protein ligase complex.
References in periodicals archive ?
CTI's research and development efforts have been focused in three areas: Procuren, CT102 and CT112.
The company is continuing to progress in the enrollment of patients for pivotal clinical trials using CT102.
CTI) (NASDAQ: CURE) today announced that the results of two controlled studies have been published providing encouraging evidence that the company's novel investigational wound healing treatment, CT102, is efficacious and more cost-effective in healing chronic non-healing wounds than conventional treatments.
CTI is developing CT102, a topical treatment containing a naturally occurring complex mixture of several growth factors derived from pooled human blood platelets, to treat chronic non-healing wounds.
A Phase II clinical study of CT102, conducted by a team of independent medical specialists, found that the most effective dosage of the therapy haled 80 percent of wounds versus 29 percent of those treated with a placebo.
No significant side effects were associated with CT102 compared to the placebo.
The cost efficacy study published in 'Wounds' evaluated the economic impact of treating patients with CT102 and a conventional treatment including a placebo.
We found that the wound healing approach incorporating CT102 as part of a comprehensive wound management program is cost-effective over several treatment options," said Dr.
We are very pleased to report that pivotal clinical trials for CT102 are underway in ten centers in the United States and either underway or beginning in over ten centers in six countries in Europe.
Clinical trials for CT102, homologous platelet releasate, are progressing.
During the fourth quarter we accelerated research and development spending related to CT102 (homologous platelet derived wound healing factor) clinical trials.